Pfizer to Buy King Pharmaceutical
By wchung | 25 Apr, 2026
Pfizer Inc., the world’s largest pharmaceutical company by revenue, said Tuesday it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash.
Pfizer is paying $14.25 per share for King. That’s a premium of 40 percent to the stock’s Monday closing price of $10.15. Pfizer gains products including the pain drug Avinza, and Embeda, an extended-release pain treatment that is designed to be abuse-resistant.
King, of Bristol, Tenn., has struggled in recent years as patents on several of its key drugs have expired or been thrown out.
The boards of both companies approved the deal. Pfizer said the purchase will add about 2 cents per share to its profit in 2011 and 2012, and 3 to 4 cents per share in each of the next three years.
In premarket trading, King shares soared to $14.12, up 39 percent from Monday’s close. Pfizer shares dipped 8 cents to $17.30.
NEW YORK (AP)
Recent Articles
- Caocao to Deploy Thousands of Cost-Efficient Robotaxis in 2027
- US to Add Firing Squads, Electrocution and Gassing to Execution Methods
- Intel Leads Soaring AI Stocks on Signs the Boom Now Includes CPUs
- US Consumer Sentiment Fell to Record Low in April
- Trump Hosts Mar-a-Lago Event for Biggest Investors in the Nearly Worthless $TRUMP Coin
- Republicans Retool Midterms Strategy to Include Less Trump
- Iran Rejects 'Maximalist Demands' Ahead of Islamabad Peace Talks
- Student Zamil Limon Found Dead, Female Friend Still Missing
- Vox Momenti: The Hot Asian Woman's Burden
- MLB’s Fraud Watch Includes Two All-Stars